Riding a wave of positive PhIII readouts, Pfizer gets a snap review for lung cancer drug dacomitinib
Pfizer’s decision to hand over four years of work on a portfolio of off-the-shelf CAR-T drugs doesn’t mean that they’re any less focused on their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
